keyword
MENU ▼
Read by QxMD icon Read
search

CALGB/SWOG 80405: Phase III trial of irinotecan

keyword
https://www.readbyqxmd.com/read/17687200/-cetuximab
#1
REVIEW
Hiroya Takiuchi
Cetuximab, an IgG1 chimeric monoclonal antibody directed against the epidermal growth factor receptor (EGFR), has been shown to have antitumor activity against EGFR-expressing colorectal cancer (CRC). Although the activity of cetuximab monotherapy is notable,cetuximab-based combinations have conferred greater benefit, with two-fold higher response rates and nearly three-fold longer progression free-survival with cetuximab plus irinotecan compared with cetuximab alone,even in irinotecan-refractory patients. Cetuximab monotherapy should be reserved for patients who cannot tolerate combination therapy...
August 2007: Gan to Kagaku Ryoho. Cancer & Chemotherapy
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"